Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | OSBP | P22059 | 6/20 | 1.00 |
| ▸ | RORC | P51449 | 5/20 | 1.00 |
| ▸ | OSBP2 | Q969R2 | 3/20 | 1.00 |
| ▸ | USP2 | O75604 | 1/20 | 1.00 |
| ▸ | LMNA | P02545 | 1/20 | 1.00 |
| ▸ | ABCB1 | P08183 | 1/20 | 1.00 |
| ▸ | CYP46A1 | Q9Y6A2 | 1/20 | 1.00 |
| ▸ | GRIN1 | Q05586 | 6/20 | 0.85 |
| ▸ | GRIN2A | Q12879 | 6/20 | 0.85 |
| ▸ | NR1H3 | Q13133 | 7/20 | 0.84 |
| ▸ | CRYAB | P02511 | 1/20 | 0.80 |
| ▸ | HMGCR | P04035 | 1/20 | 0.80 |
| ▸ | ITGB3 | P05106 | 1/20 | 0.80 |
| ▸ | ITGAV | P06756 | 1/20 | 0.80 |
| ▸ | SREBF2 | Q12772 | 1/20 | 0.80 |
| ▸ | NPC1L1 | Q9UHC9 | 1/20 | 0.80 |
| ▸ | GRIN2B | Q13224 | 5/20 | 0.80 |
| ▸ | DHCR24 | Q15392 | 1/20 | 0.77 |
| ▸ | EPHA2 | P29317 | 1/20 | 0.75 |
| ▸ | NR1H2 | P55055 | 1/20 | 0.74 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Cholesterol SCHEMBL21707472 | 1.00 | OSBP (1.00) | OSBPRORCOSBP2USP2LMNA | |
| Cholesterol SCHEMBL21539517 | 1.00 | OSBP (1.00) | OSBPRORCOSBP2USP2LMNA | |
| Cholesterol SCHEMBL22095727 | 1.00 | OSBP (1.00) | OSBPRORCOSBP2USP2LMNA | |
| Cholesterol SCHEMBL21447271 | 1.00 | OSBP (1.00) | OSBPRORCOSBP2USP2LMNA | |
| Cholesterol SCHEMBL23579652 | 1.00 | OSBP (1.00) | OSBPRORCOSBP2USP2LMNA | |
| Cholesterol SCHEMBL23365796 | 1.00 | OSBP (1.00) | OSBPRORCOSBP2USP2LMNA | |
| Cholesterol SCHEMBL21650234 | 1.00 | OSBP (1.00) | OSBPRORCOSBP2USP2LMNA | |
| Cholesterol SCHEMBL23761109 | 1.00 | OSBP (1.00) | OSBPRORCOSBP2USP2LMNA | |
| Cholesterol SCHEMBL21445079 | 1.00 | OSBP (1.00) | OSBPRORCOSBP2USP2LMNA | |
| Cholesterol SCHEMBL20607477 | 1.00 | OSBP (1.00) | OSBPRORCOSBP2USP2LMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 103 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12569501-B2 | Neurosteroids and enantiomers thereof for the prevention and treatment of neurodegenerative conditions | WASHINGTON UNIVERSITY (US) | 2026-03-10 | — | — | US | claimed |
| US-20240041898-A9 | NEUROSTEROIDS AND ENANTIOMERS THEREOF FOR THE PREVENTION AND TREATMENT OF NEURODEGENERATIVE CONDITIONS | WASHINGTON UNIVERSITY | 2024-02-08 | — | — | US | claimed |
| US-20230058339-A1 | NEUROSTEROIDS AND ENANTIOMERS THEREOF FOR THE PREVENTION AND TREATMENT OF NEURODEGENERATIVE CONDITIONS | WASHINGTON UNIVERSITY ST LOUIS | 2023-02-23 | — | — | US | claimed |
| US-20230043677-A1 | INHALABLE THERAPEUTICS | OREGON STATE UNIVERSITY (US) | 2023-02-09 | — | — | US | claimed |
| WO-2026098601-A1 | LIPID NANOPARTICLE FOR DELIVERING LOAD | 北京剂泰生命科技有限公司 | 2026-05-15 | — | — | WO | disclosed |
| US-20260124157-A1 | METHODS OF SELF-AMPLIFYING RNA-LIPID NANOPARTICLE MANUFACTURE AND COMPOSITIONS DERIVED THEREFROM | GENVAX TECH INC (US) | 2026-05-07 | — | — | US | disclosed |
| EP-4683905-A1 | IONIZABLE ANIONIC LIPIDS | Nanovation Therapeutics Inc. (CA) | 2026-01-28 | — | — | EP | disclosed |
| EP-4676446-A1 | NOVEL LIPID NANOPARTICLE FORMULATIONS FOR DELIVERY OF NUCLEIC ACIDS | CureVac SE (DE) | 2026-01-14 | — | — | EP | disclosed |
| US-12458604-B2 | Methods of lipid nanoparticle manufacture and compositions derived therefrom | THE TRUSTEES OF THE UNIVERSITY OF PENNSYLVANIA (US) | 2025-11-04 | — | — | US | disclosed |
| WO-2025213271-A1 | METHOD OF DELIVERING NUCLEIC ACID TO MACROPHAGES AND/OR MONOCYTES AND COMPOSITIONS FOR USE THEREOF | NANOVATION THERAPEUTICS INC. (CA) | 2025-10-16 | — | — | WO | disclosed |
| WO-2025213270-A1 | METHOD OF DELIVERING NUCLEIC ACID TO T CELLS AND COMPOSITIONS FOR USE THEREOF | NANOVATION THERAPEUTICS INC. (CA) | 2025-10-16 | — | — | WO | disclosed |
| EP-4630061-A1 | LIPID NANOPARTICLES COMPRISING ELEVATED NEUTRAL LIPID AND A TARGETING MOIETY FOR TARGETED DELIVERY OF NUCLEIC ACID | Nanovation Therapeutics Inc. (CA) | 2025-10-15 | — | — | EP | disclosed |
| WO-2022140404-A1 | ZWITTERIONIC LIPID NANOPARTICLE COMPOSITIONS, AND METHODS OF USE | CORNELL UNIVERSITY (US) | 2022-06-30 | — | — | WO | disclosed |
| EP-3539031-B1 | SKIN PERMEABILITY PREDICTION | ERCO PHARMA AB (SE) | 2022-06-29 | — | — | EP | disclosed |
| EP-3997117-A1 | COMPOSITIONS AND METHODS FOR ENHANCING CELL CULTURE | Life Technologies Corporation (US) | 2022-05-18 | — | — | EP | disclosed |
| WO-2022081752-A1 | METHODS OF LIPID NANOPARTICLE MANUFACTURE AND COMPOSTIONS DERIVED THEREFROM | George Mason Research Foundation, Inc. (US) | 2022-04-21 | — | — | WO | disclosed |
| CN-114222813-A | Compositions and methods for enhancing cell culture | 生命技术公司 | 2022-03-22 | — | — | CN | disclosed |
| WO-2022040641-A2 | FUNCTIONAL IONIZABLE PHOSPHOLIPIDS | THE BOARD OF REGENTS OF THE UNIVERSITY OF TEXAS SYSTEM (US) | 2022-02-24 | — | — | WO | disclosed |
| US-20190307690-A1 | Liposomal Delivery Systems for Oxaliplatin and in Dual Drug Delivery in Combination with Chemo-sensitizing and Chemo-therapeutic agents | THE AMERICAN UNIVERSITY IN CAIRO | 2019-10-10 | — | — | US | disclosed |
| US-20190279743-A1 | SKIN PERMEABILITY PREDICTION | ERCO PHARMA AB (SE) | 2019-09-12 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12569501-B2 | Neurosteroids and enantiomers thereof for the prevention and treatment of neurodegenerative conditions | ATG13, GSK3B, HSD11B1 | OSBP 966/4885RORC 393/4885OSBP2 1193/4885 |
| US-12458604-B2 | Methods of lipid nanoparticle manufacture and compositions derived therefrom | RNMT, HNRNPM, AUP1 | OSBP 526/4885RORC 840/4885OSBP2 289/4885 |
| US-20260124157-A1 | METHODS OF SELF-AMPLIFYING RNA-LIPID NANOPARTICLE MANUFACTURE AND COMPOSITIONS DERIVED THEREFROM | HNRNPM, SARNP, SNRPF | OSBP 732/4885RORC 2721/4885OSBP2 1039/4885 |
| US-20230043677-A1 | INHALABLE THERAPEUTICS | RNMT, CETP, NPC1L1 | OSBP 618/4885RORC 171/4885OSBP2 459/4885 |
| US-20190307690-A1 | Liposomal Delivery Systems for Oxaliplatin and in Dual Drug Delivery in Combination with Chemo-sensitizing and Chemo-therapeutic agents | TTPA, SLC5A6, CACNG6 | OSBP 178/4885RORC 3080/4885OSBP2 236/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.